PD-L1 as a Biomarker for Immunotherapy; Imperfect but Important

By | 3 December 2025
  • Reflecting on the immuno-oncology Dx landscape
  • Discussing challenges for integrating CDx in immuno-oncology trials
  • Navigating what’s next for immunotherapy CDx?